Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Ostrowiec Swietokrzyski – page 5

81 clinical trials in Ostrowiec Swietokrzyski, Poland across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Ostrowiec Swietokrzyski at a glance
81
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

81 trials in Ostrowiec Swietokrzyski

Open in trial search

Chronic obstructive pulmonary disease

Not recruiting

A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Chronic obstructive pulmonary disease

Not recruiting

A Study of Inhaled Fexlamose for Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:6-THIO-ALFA-D-GLUCOPYRANOSYL 6-THIO-ALFA-D-GLUCOPYRANOSIDE
  • Sponsor:Aer Therapeutics Inc.

Chronic obstructive pulmonary disease

Not recruiting

Study of tozorakimab to reduce exacerbations in former smokers with chronic obstructive pulmonary disease (COPD)

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:AstraZeneca AB

Asthmatic crisis

Not recruiting

Long-term safety and effectiveness study of verekitug injections in adults with severe asthma who completed the VALIANT trial

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 kappa monoclonal antibody against CRLF2
  • Sponsor:Upstream Bio Inc.

Hidradenitis

Not recruiting

Study of Bimekizumab for Children and Adolescents with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Lunsekimig (SAR443765) for Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lunsekimig
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Psoriasis

Not recruiting

Study on the Effects of IDP-122 Lotion for Children with Moderate to Severe Plaque Psoriasis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 65+ years
  • Substances:Halobetasol propionate
  • Sponsor:Bausch Health Americas Inc.

Chronic obstructive pulmonary disease

Not recruiting

Study on Atorvastatin for Reducing COPD Exacerbations in Smokers with Chronic Obstructive Pulmonary Disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Agencja Badań Medycznych

Cough

Not recruiting

Study on the Effectiveness and Safety of Taplucainium Inhalation Powder (NOC-110) for Adults with Refractory or Unexplained Chronic Cough

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Taplucainium Chloride
  • Sponsor:Nocion Therapeutics Inc.

Chronic obstructive pulmonary disease

Not recruiting

Study on the Effects of Itepekimab in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Chronic obstructive pulmonary disease

Not recruiting

Study on Itepekimab for Former Smokers with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Asthma

Not recruiting

Study on the Effects of Dexpramipexole in Adolescents and Adults with Eosinophilic Asthma

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dexpramipexole Dihydrochloride Monohydrate
  • Sponsor:Areteia Therapeutics Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Ostrowiec Swietokrzyski

What the registry says about research in the country

01 Respiratory Conditions

Important clinical research focusing on asthma and COPD management, including trials evaluating new inhaler formulations and innovative treatments for severe cases.

  • Asthma control and exacerbation prevention
  • COPD treatment optimization
  • Bronchiectasis management

Studies include evaluation of triple therapy combinations and novel biological treatments for better disease control.

02 Dermatological Disorders

Comprehensive research into various skin conditions, with particular focus on atopic dermatitis, psoriasis, and other inflammatory skin disorders.

  • Moderate to severe plaque psoriasis
  • Atopic dermatitis treatments
  • Vitiligo and alopecia therapies

Trials examine both topical and systemic treatments, including novel biological therapies.

03 Cardiovascular Research

Innovative studies targeting atherosclerotic cardiovascular disease, focusing on prevention and treatment of major cardiovascular events.

  • Lipid-modifying therapies
  • Cardiovascular risk reduction
  • Prevention of major adverse cardiac events

Research includes evaluation of new compounds for managing cholesterol levels and preventing cardiovascular complications.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.